Definitive Contract 75N93023C00013
Award Date 7/1/23
Potential Completion Date 6/30/26
Potential Value $3.3M
Federal Agency
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Wauwatosa, WI 53226, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
16
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $4,223,612 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Ceramedix Holding, LLC, a small disadvantaged business, for the development of an anticeramide treatment as a novel medical countermeasure for the acute effects of radiation exposure. The contract has a period of performance ending on June 30, 2026. The contract involves two subcontractors: the Sloan-Kettering Institute for Cancer Research, which will characterize...
- This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Meabco Inc. for the "ERMES EVALUATION OF RADIOMITIGATIVE EFFICACY AND SAFETY OF BP-C2" project. The contract has a ceiling value of $6,434,348.32 and a period of performance ending on April 30, 2025. The contract stems from a Broad Agency Announcement (BAA) seeking proposals to develop safe and effective medical countermeasures to...
- This $4,175,467 definitive cost-no-fee contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Pluri Biotech LTD, a for-profit limited liability company based in Israel, for the development of PLX-R18 cell therapy as a countermeasure for hematopoietic acute radiation syndrome. The contract, which has no set-aside designation, supports research and development efforts focused on creating safe and effective medical countermeasures to mitigate...
- The National Institute of Allergy and Infectious Diseases (NIAID) of the Department of Health and Human Services awarded a $6,620,728 cost-plus-fixed-fee contract to Xequel Bio, Inc. (doing business as FSR) to develop a topical therapeutic called GRANEXIN to mitigate cutaneous radiation injury. This contract was awarded under a prior NIAID Broad Agency Announcement that sought proposals for advanced development of medical countermeasures, including those targeting radiation exposure. The...
- This is a $81,904,328.96 cost-no-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to the University of Maryland, Baltimore (UMB) for radiation/nuclear medical countermeasure product development support services. The contract supports the development of medical countermeasures against radiation and nuclear threats, which aligns with NIAID's mission to conduct and support research to...
- This federal contract award, valued at $2,089,751.30, was granted to The Medical College of Wisconsin, Inc. (MCW) to conduct research on the effects of microgravity and space radiation on cardiac disease. The award is intended to address key aspects of the research goals outlined in Topic 6 of the National Research Announcement (NRA) NNJ16ZSA001N-SRHHC, which focuses on Space Radiation and Human Health Countermeasures. The proposed research aims to 1) provide detailed physiological and...
- This federal contract award to Innovation Pathways, LLC, a for-profit limited liability company, is for the pharmacological development of IPW-5371 fumarate as a radiation medical countermeasure for the treatment of delayed radiation lung injury under the FDA Animal Rule. The $3,499,688.00 cost-plus-fixed-fee contract was awarded by the National Institute of Allergy and Infectious Diseases, a civilian agency, and has no set-aside designation. The contract work supports research and development...
- This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), to SRI International, a non-profit research and development institute. The contract, valued at $715,633.86, is for radiation/nuclear medical countermeasure (MCM) product development support services, specifically the formulation of 3,4,3-Li(1,2-HOPO). This contract is not a set-aside and is part of a...
- This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to SRI International, a non-profit research and development institute. The contract has a ceiling value of $11,180,527.00 and is a Delivery Order with a Cost Plus Fixed Fee pricing type. The contract is for animal model development and efficacy testing, with a period of performance through September 29, 2026. The contract has two subcontractors: The Medical College of...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $31,725,938.61 cost-plus-fixed-fee contract to Revagenix Inc. to select a novel small molecule antibiotic for clinical development and advance it through IND filing and Phase 1 clinical studies. This contract was not set aside and has an ultimate completion date of August 31, 2026. The contract originated from a NIAID Broad Agency Announcement seeking proposals to develop medical countermeasures to mitigate and/or...